Clinical Trial Update: Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and immunogenicity of a plant-derived Pfs25 VLP-FhCMB malaria transmission-blocking vaccine in healthy adults; study completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Pfs25 VLP-FhCMB malaria transmission-blocking vaccine

Snippet

Sponsor: Fraunhofer, Center for Molecular Biotechnology | Conditions: Malaria | Phase 1 | Status: COMPLETED | Results posted: 2017-01-18